About this event

  • Date and time Wed 13 Mar 2019 from 8:45am to 5:05pm
  • Location Royal Society of Medicine
  • Organised by Respiratory Medicine

The Royal Society of Medicine commemorates The World TB Day with an annual TB meeting to review the most relevant advances in clinical, public health and scientific aspects of TB, organised by Professor Ajit Lalvani of the National Heart & Lung Institute, Imperial College London. This annual TB meeting will look at recent progress and the path towards elimination. Key speakers from all around the world will come together to look at the end strategy, the declining trend, new diagnostic tools and an update since last year introduction of Whole Genome Sequencing (WGS). 

The World TB Day, on March 24th, is designed to build public awareness that tuberculosis today remains an epidemic in much of the world, causing the deaths of nearly one-and-a-half million people each year, mostly in developing countries. It commemorates the day in 1882 when Dr Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. At the time of Koch's announcement in Berlin, TB was raging through Europe and the Americas, causing the death of one out of every seven people. Koch's discovery opened the way towards diagnosing and curing TB.

There are a number of bursary places available for nurses. To be considered, just email events@rsm.ac.uk detailing why you would benefit from this meeting in no more than 200 words. 

Topics include:

- Understand what the end strategy looks like

- Assess TB transmission by analysing relapse versus reinfection

- Know about the impacts of screening and the WGS prevention method

- Understand the natural resistance and ways in which this can be harnessed


We would like to thank our exhibitors:

QIAGEN and Oxford Immunotec

Please note that none of the companies listed has had any influence or involvement over the agenda, content or organisation of this meeting.

Key speakers

Professor Mark Hatherill

Director of South African Tuberculosis Vaccine Initiative (SATVI) & Full Member of the Institute of Infectious Disease and Molecular Medicine (IDM), University of Cape Town

Speaker's biography

SATVI is a world leader in TB vaccine clinical research. Their mission is the development of new and effective vaccination strategies against tuberculosis (TB). They are testing multiple new vaccine candidates in clinical trials; and are involved with projects to address critical clinical, epidemiological, immunological and human genetic questions in TB vaccine development. Activities are within an academic context, and thus include the training of postgraduate students. 

The team of over 100 staff consists of specialists in: clinical, epidemiological, human genetic and immunologic science, clinical trials, community liaison, recruitment and follow-up; data management and analysis, disease surveillance, information technology, clinical evaluation and care of participants; facility management, laboratory technology, logistics, research pharmacy management, project management, regulatory affairs, administration, study coordination and training. 

Professor Hatherill’s clinical research interests have focused on design, implementation, and analysis of clinical trials of BCG vaccine and novel TB vaccines candidates; diagnostic studies of TB infection and disease in adult and paediatric study populations; and TB therapeutic clinical trials. A major new project will test targeted TB preventive therapy for high risk persons identified by a novel transcriptomic correlate of risk assay.

Further details are found here [www.satvi.uct.ac.za]

Ajit Lalvani

Professor Ajit Lalvani

Chair of Infectious Diseases, National Institute of Health Research Senior Investigator and Wellcome Senior Clinical Research Fellow at Imperial College London. Founding Director of the Tuberculosis Research Centre.

Speaker's biography

Ajit Lalvani is Head of Respiratory Infection and Director of the TB Research Centre at IC. He invented and validated the paradigm of T cell-based diagnosis (ELISpot-IGRA), the NICE-approved standard-of-care for LTBI which transformed TB control and prevention nationally and internationally. His more recent work dissected the epidemiology of TB in the UK, systematically assessed and critiqued existing policy and practice for new-entrant TB screening and developed a new cost-effective strategy to identify >90% of imported latent TB.


Dr Sarah Anderson

Sarah Anderson currently works at Public Health England as Head of TB Strategy leading the implementation of the Collaborative TB Strategy for England, 2015-2020. 

Speaker's biography

Dr Sarah Anderson is Head of TB Strategy at Public Health England and in this role, is leading the implementation of the Collaborative TB Strategy for England, 2015-2020. Sarah previously worked as a London Regional Epidemiologist, a Consultant in Health Protection and as PHE London’s TB lead. She is currently a member of the Technical Advisory Group on TB for the WHO Regional Office for Europe and has recently been invited to join the European Sciana Health Leaders Network.

Sarah trained as a doctor in Cambridge and London and undertook a medical doctorate researching ‘The epidemiology of TB from a primary care perspective’. She has spent time seconded to the WHO, Stop TB Department in Geneva where she published research on improving international TB and HIV collaboration; and has an academic interest in TB with a number of on-going TB research projects; publishing most recently as part of the PREDICT Study: ‘Prognostic value of interferon-γ release assays and tuberculin skin test in predicting the development of active tuberculosis: a prospective cohort study’ in Lancet Infectious Diseases and in Thorax a ‘Reduction in tuberculosis incidence in the UK from 2011 to 2015: a population-based study’.

In 2019, Sarah will be awarded the Bisset Hawkins Medal of the Royal College of Physicians, a triennial award, given to acknowledge work undertaken in the preceding ten years to advance sanitary science or promote public health.

Alice Halliday

Dr Alice Halliday

Honorary Research Associate, Faculty of MedicineNational Heart & Lung Institute, Imperial College London

Speaker's biography

Dr Alice Halliday received her BSc in Microbiology from the University of Manchester in 2008. She subsequently worked as a research assistant on an NHS-funded project exploring health care needs in relation to immunisation uptake in Manchester. She then moved back to laboratory science, gaining a PhD from the Liverpool School of Tropical Medicine (LSTM) exploring the immune responses to Leishmania infection. Her first postdoc, also at LSTM, involved the development of models of Onchocerciasis for drug screening, both in the UK and in Cameroon.

In 2014, Dr Halliday moved to Imperial College where her work has been focused on exploring cellular immune responses in Tuberculosis, with a particular interest in the development of new diagnostic tools. By interogating immune responses to Mycobacterium tuberculosis antigens using flow cytometry, it has been shown that it is possible to differentiate between different stages of Tuberculosis infection in humans. Dr Halliday aims to validate this approach using large biobanks of samples, taken from patients with the full spectrum of active and latent Tuberculosis infection, with the aim of developing improved diagnostic tests. 

Dr Grace Smith

Dr Grace Smith

Clinical Director for Infectious Diseases and Sexual health in Heart of England NHS Foundation Trust, Chair of the multidisciplinary Clinical Group for the Birmingham and Solihull TB Control Programme, Clinical lead for PHE, (HPA) Mycobacterial Reference Service for the Midlands since 1995, 

Speaker's biography

Professor Grace Smith oversees a very active clinical practice in acute bacteriology and primary and reference mycobacteriology in a high incidence area. She has led the introduction of MIRU VNTR typing into regular clinical service.

Dr Esther Robinson

Lead Public Health Microbiologist, Public Health England

Speaker's biography

A clinical academic who gained her medical degree at the University of Oxford, along with a bachelor’s degree in Physiology, hospital junior doctor jobs developed Esther’s interest in infection and antibiotic resistance. This work led to a training programme in medical microbiology and virology, initially in the West Midlands and later in Oxford.

Her DPhil thesis, with Professor Derrick Crook of the Modernising Medical Microbiology consortium in Oxford, was on horizontal transfer of antibiotic resistance. She has also collaborated with work on transferable genetic elements in Clostridium difficile and multiply-resistant gram negative organisms.

As a clinician, she deals daily with the challenges of hospital-acquired infection and antibiotic resistance and this directly stimulates her research, where she is developing her interests in the genomic epidemiology of bacteria and their resistance genes, alongside an honorary consultant medical microbiologist post at the Heart of England Foundation Trust.

Dr Pranab Haldar

Clinical Senior Lecturer and Training Programme Director at University of Leicester

Speaker's biography

Dr Pranab Haldar research includes TB prevention strategies and the epidemiology of M.tuberculosis infection, with a particular focus on the utility of diagnostic tools for characterising future TB risk and their implementation in screening programs; and role of eosinophilic inflammation in the clinical expression of asthma.


View the programme

Registration, tea and coffee
Introduction to the day

Professor Ajit Lalvani, Director, NIHR Health Protection Research Unit (HPRU) in Respiratory Infections, Director, Tuberculosis Research Centre, Imperial College London

WHO the end TB strategy

Dr Mirae Park, Clinical Research Fellow, Imperial Clinical Respiratory Research Unit, St Mary’s Hospital

Declining TB trend in the UK: Why and where next?

Dr Sarah Anderson, National Lead for TB Strategy, Public Health England

Characterising Recurrent TB in the UK: Clinical and Genomic Insights

Dr Clemmie Fraser, NIHR Health Protection Research Unit (HPRU) in Respiratory Infections, Imperial College London and Jennifer Davidson, Public Health England

Impact of screening new entrants for latent and active TB

Dr. Luis C. Berrocal Almanza, Research associate, NIHR HPRU in Respiratory Infections at Imperial College London

Impact of whole genome sequencing on TB prevention

Dr Grace Smith and Dr Esther Robinson, Public Health England

Tea and coffee break
Accelerating TB diagnosis in underserved populations

Helen Piotrowski, Health Protection Research Unit (HPRU) in Respiratory Infections, Imperial College London and Hanna Kaur, TB Lead Nurse at Heart of England NHS Foundation Trust

Illustrative clinical cases

Dr Pranab Haldar, Clinical Senior Lecturer and Training Programme Director, University of Leicester

Questions and answers with expert panel
The Sir John Crofton Memorial Lecture: New effective TB vaccines

Professor Mark Hatherill, Director, South African Tuberculosis Vaccine Initiative (SATVI), University of Cape Town

Epidemiological considerations for TB elimination: Targeting recent infection

Lalita Ramakrishnan, University of Cambridge

The new MDR-TB guidance: Can we afford not to do it?

Professor Onn Min Kon, Respiratory Physician and Head of Service for Tuberculosis at Imperial College London Healthcare NHS Trust

Tea and coffee break
Natural resistance to TB infection: What is it and how can we harness it?

Dr Reinout van Crevel, Center for Infectious Diseases, Radboud University, Netherlands 

Questions and answers with expert panel
Closing remarks
Completion of evaluation forms and close of meeting
Drinks reception



Royal Society of Medicine, 1 Wimpole St, Marylebone, London, W1G 0AE, United Kingdom